BioCentury | Feb 13, 2020
Emerging Company Profile

Pneumagen: out-competing viral sugar binding to prevent infection

With its platform of carbohydrate-binding proteins, Pneumagen is co-opting a pathogenic tool for interacting with host cells to block infections and adapting the technology for use against cancer. Both viruses and bacteria can interact with...
BioCentury | Feb 8, 2020
Tools & Techniques

Beyond PROTACs and the proteasome: broadening the TAC toolbox

The idea of sending disease-driving proteins to the cell’s garbage can is only the first act in a field that now centers around targeted degradation. In the sequel, researchers are extending the principle to other...
BioCentury | Jan 4, 2020
Targets & Mechanisms

SIGLECs go from homing beacons to next-generation checkpoints

Propelled by growing understanding of their biology, and an expression pattern that goes well beyond T cells, SIGLEC proteins are rising as the next set of checkpoint targets to challenge PD-1. The sugar-binding proteins could...
BC Innovations | Dec 5, 2019
Emerging Company Profile

VaxNewMo: bioconjugating antibacterial vaccines

VaxNewMo is developing a bioengineered platform that could yield inexpensive glyconjugate vaccines that prevent bacterial infections, including those not yet covered by existing vaccines. Traditional chemical glycoconjugation is laborious and expensive, as it typically involves...
BC Extra | Aug 13, 2019
Clinical News

Two Ebola therapies best ZMapp in Congo trial

All patients in an Ebola trial in the Democratic Republic of the Congo will be offered treatments from Regeneron and NIAID after they were shown to be superior to ZMapp in preventing death in the...
BC Extra | Aug 7, 2019
Financial News

Glycomine looks toward clinic with Novo-led $33M round

Glycomine raised a tranched $33 million series B round to take its lead rare congenital disease therapy into the clinic. Novo Holdings A/S led the round. Additional new investors Asahi Kasei Pharma Corp. and Mission...
BC Week In Review | Nov 30, 2018
Clinical News

Fauci details goals of new Ebola trial

The first randomized, controlled trial of potential Ebola therapies conducted during an outbreak has started enrolling patients in the Democratic Republic of Congo. The trial is intended to treat patients who are affected by an...
BC Innovations | Aug 23, 2018
Distillery Techniques


TECHNOLOGY: Biosynthesis An E. coli -based method could be used to produce glycosylated versions of proteins as therapies and vaccine components. The method involves three steps: engineering E. coli with plasmids that express components of...
BC Innovations | Jun 20, 2018
Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy A method utilizing click chemistry to generate injectable hydrogels containing cross-linked cells could be used in regenerative therapies. The method generates hydrogels containing cross-linked cells in three steps: metabolic incorporation of azide...
BC Week In Review | Jun 8, 2018
Company News

DRC approves compassionate use of investigational Ebola treatments

A Democratic Republic of the Congo ethics committee approved the use of five investigational Ebola therapies under compassionate use and expanded access. The World Health Organization said four of the five approved products are in...
Items per page:
1 - 10 of 122